We are live on ! Find out more
CM

Crestline Management Portfolio holdings

AUM $46.3M
1-Year Est. Return 48.82%
This Fund
S&P 500
This Quarter Est. Return
-6.42%
1 Year Est. Return
+48.82%
3 Year Est. Return
+52.52%
5 Year Est. Return
+37.91%
10 Year Est. Return
+316.44%
AUM
$976M
AUM Growth
+$257M
Cap. Flow
+$279M
Cap. Flow %
28.55%
Top 10 Hldgs %
76.43%
Holding
234
New
114
Increased
26
Reduced
16
Closed
77

Sector Composition

Rank Sector Weight
1 Healthcare 37.59%
2 Financials 12.34%
3 Technology 4.43%
4 Industrials 4.41%
5 Consumer Discretionary 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ARRY
226
DELISTED
Array Biopharma Inc
ARRY
-59,291
Closed -$729K
TVPT
227
DELISTED
Travelport Worldwide Limited
TVPT
-147,141
Closed -$2.31M
ELLI
228
DELISTED
Ellie Mae Inc
ELLI
-30,530
Closed -$2.51M
DNB
229
DELISTED
Dun & Bradstreet
DNB
-25,933
Closed -$3.02M
DISH
230
DELISTED
DISH Network Corp.
DISH
-64,973
Closed -$3.52M
TSS
231
DELISTED
Total System Services, Inc.
TSS
-18,506
Closed -$1.21M
DST
232
DELISTED
DST Systems Inc.
DST
-78,332
Closed -$4.3M
STL
233
DELISTED
Sterling Bancorp
STL
-170,000
Closed -$4.19M
FDC
234
DELISTED
First Data Corporation
FDC
-134,460
Closed -$2.43M

Similar funds

Crestline Management's Q4 2017 Portfolio in Review

As of Q4 2017, Crestline Management held 234 positions worth $976M, up 36% from $719M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Crestline Management deployed $279M of net new capital in Q4 2017, opening 114 new positions and adding to 26 existing holdings. Its largest new stake was Denali Therapeutics: 20,574,298 shares worth $322M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 5.7% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Juno Therapeutics, Inc., an estimated $85.7M trimmed.

  • Crestline Management's largest Q4 2017 buy was Denali Therapeutics: 20,574,298 shares worth $322M.
  • Crestline Management added most to Ameriprise Financial in Q4 2017, an estimated $7.55M increase.
  • Crestline Management's biggest Q4 2017 reduction was Juno Therapeutics, Inc., cutting an estimated $85.7M.
  • Crestline Management fully exited FNB Corp in Q4 2017, selling an estimated $8.22M.
  • Crestline Management's ten largest holdings make up 76% of its $976M portfolio in Q4 2017.
  • Crestline Management opened 114 new positions and closed 77 in Q4 2017.
  • Crestline Management's portfolio value rose 36% quarter-over-quarter to $976M.

Based on Crestline Management's 13F filing for Q4 2017, filed 14 Feb 2018.